Antibody Clinical Trials Drug Delivery Systems FDA Approval 
XTalks
AUGUST 14, 2024
The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.
XTalks
OCTOBER 27, 2021
Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
NOVEMBER 29, 2020
Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market. Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market.
XTalks
AUGUST 30, 2022
Filipe Rodrigues, MD/MSc, Medical Director at Medpace spoke about the modern-day applications of direct CNS administration, including intrathecal, intraparenchymal and ICV delivery. Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. Figure 3 ).
The Pharma Data
AUGUST 31, 2021
S ites and Burden of Metastases and Long-Term Outcomes in TITAN Patients (moderated poster session) : Assessment of relationships between the number and location of metastases and oncological outcomes in 1,052 patients with metastatic castration-sensitive prostate cancer (mCSPC) enrolled in the TITAN trial (Abstract #MP24-08). About TAR-200.
Expert insights. Personalized for you.
98 
Let's personalize your content